PolyPid Ltd PYPD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
-
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
-
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
-
PolyPid Announces Participation in Upcoming Fall Investor Conferences
-
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
-
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
-
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
-
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
Trading Information
- Previous Close Price
- $4.90
- Day Range
- $4.72–4.90
- 52-Week Range
- $3.10–5.73
- Bid/Ask
- $4.70 / $4.90
- Shares Outstanding
- 20.31M
- Market Cap
- $95.87M
- Volume/Avg
- 150,736 / 167,845
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.polypid.com
Valuation
|
Metric
|
PYPD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 17.79 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PYPD
|
|---|---|
Quick Ratio | 0.99 |
Current Ratio | 1.35 |
Interest Coverage | — |
Quick Ratio
PYPD
Profitability
|
Metric
|
PYPD
|
|---|---|
Return on Assets (Normalized) | −115.76% |
Return on Equity (Normalized) | −230.12% |
Return on Invested Capital (Normalized) | −176.17% |
Return on Assets
PYPD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yD$q?^$ | LOCK|NCV> | $127B | |||
| Moderna Inc
MRNA
| LOCK|>%&$P^Z | LOCK|@Sv | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$tcT^!$ | LOCK|Cb@zR | $81B | |||
| argenx SE ADR
ARGX
| LOCK|nt<F<H | LOCK|Ht | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|sN$Z$w | LOCK|W@q | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|YRr?$< | LOCK|#G!@ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>vfD&HQ | LOCK|$h#Y? | $27B | |||
| Incyte Corp
INCY
| LOCK|Ht!&h? | LOCK|^& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|nNC!>dp | LOCK|># | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%PCzdGG | LOCK|W@ | $14B |
United States